Morgan Stanley analyst Stephen Byrd downgrades Array Technologies (NASDAQ:ARRY) from Equal-Weight to Underweight and lowers the price target from $17 to $15.
Where Harmony Biosciences Stands With Analysts
Analysts have provided the following ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter: